Track topics on Twitter Track topics that are important to you
Monday, July 31st 2017 at 3:45pm UTC STRASBOURG, France–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Transgene (Paris:TNG), a company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated in a Phase 1/2 clinical trial evaluating the combination of Pexa-Vec with Opdivo® (nivolumab) as a first-line treatment of advanced hepatocellular carcinoma (HCC), which …
Cet article Transgene: First Patient Dosed in a Phase 1/2 Trial of
Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer est apparu en premier sur EEI-BIOTECHFINANCES.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...